🟢 Revolution Medicines is trading 6.2% up in pre-market after RASONQUE revenue topped expectations

Revolution Medicines is trading at $212.00, up 6.16% in pre-market after a strong RASONQUE launch.

• The November 4 report showed $197.6 million in RASONQUE revenue from roughly five weeks of U.S. sales.
• Management cautioned that early revenue included finite patient transitions and initial inventory stocking, and should not be taken as representative of the longer-term trajectory.
• A narrower-than-expected loss also supported the rise. The company reiterated 2026 operating-expense guidance; the official release did not announce a revenue-guidance raise.